维普中文期刊产品整合服务

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer:a subpopulation analysis of the JACOB trial

查看全文 作　　者：Tianshu [1]Liu;Yanru [2]Qin;Jin [3,4]Li;Ruihua [5]Xu;Jianming [6]Xu;Shujun [7]Yang;Shukui [8]Qin;Yuxian [9]Bai;Changping [10]Wu;Yixiang [11]Mao;Haiyan [11]Wu;Yilin [12]Ge;Lin [13]Shen 高影响力作者 机构地区：[1]Department of Oncology,Zhongshan Hospital,Fudan University,Shanghai 200032,P.R.China;[2]Department of Clinical Oncology,The First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,Henan,P.R.China;[3]Department of Medical Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,P.R.China;[4]Department of Oncology,Tongji University Eastern Hospital,Shanghai 200120,P.R.China;[5]Department of Medical Oncology,Sun Yat-Sen University Cancer Center,Guangzhou 510060,Guang-dong,P.R.China;[6]Department of Oncology,307th Hospital of PLA,Academy of Military Medical Sciences,Beijing 100071,P.R.China;[7]Department of Medical Oncology,Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,Zhengzhou 450008,Henan,P.R.China;[8]Department of Oncology,People’s Liberation Army(PLA)Cancer Center,81st Hospital of PLA,Nanjing 210002,Jiangsu,P.R.China;[9]Medical Department,Harbin Medical University Cancer Hospital,Harbin 150081,Heilongjiang,P.R.China;[10]Department of Oncology,First People’s Hospital of Changzhou,Changzhou 213003,Jiangsu,P.R.China;[11]Roche(China)Holding Co.,Ltd.,Shanghai 201203,P.R.China;[12]Medical Division,Shanghai Roche Pharmaceuticals Ltd.,Shanghai 201203,P.R.China;[13]Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Gastrointestinal Oncology,Peking University Cancer Hospital and Institute,#52 Fucheng Road,Haidian District,Beijing 100142,P.R.China高影响力机构 出　　处：《Cancer Communications》索引2019年第39卷第1期,共10页高影响力期刊 基　　金：This post hoc analysis was sponsored by Shanghai Roche Pharmaceuticals Ltd.,China.Shanghai Roche Pharmaceuticals Ltd.,China was involved in the data interpretation and writing of the report.F.Hoffmann-La Roche Ltd.was involved in the study design,data collection,and data analysis 摘　　要：Background:The JACOB trial(NCT01774786)was a double-blinded,placebo-controlled,randomized,multicenter,international,phase III trial evaluating the efficacy and safety of adding pertuzumab to trastuzumab and chemo-therapy in first-line treatment of human epidermal growth factor receptor 2(HER2)-positive metastatic gastric cancer/gastroesophageal junction cancer(GEJC).The aim of this analysis was to investigate efficacy and safety outcomes in the Chinese subpopulation from the JACOB trial.Methods:This post hoc subpopulation analysis included all patients recruited in China's Mainland(n=163;20.9%)between June 2013 and January 2016.The patients were randomly assigned in a 1:1 ratio to receive pertuzumab plus trastuzumab and chemotherapy(pertuzumab group;n=82)or placebo plus trastuzumab and chemotherapy(con-trol group;n=81).Intravenous pertuzumab(840 mg)and trastuzumab(8 mg/kg loading and 6 mg/kg maintenance doses)were given every 3 weeks until disease progression or unacceptable toxicity.Chemotherapy was given as per standard regimens/doses of capecitabine or 5-fluorouracil plus cisplatin.The primary endpoint was overall survival(OS);secondary efficacy endpoints included progression-free survival(PFS),and overall objective response rate(ORR).Results:The median OS was 18.7 months in the pertuzumab group and 16.1 months in the control group(hazard ratio[HR]0.75;95%confidence interval[CI]0.49 to 1.14).The median PFS was 10.5 and 8.6 months in the pertuzumab and control groups,respectively(HR 0.85;95%CI 0.60 to 1.21),and the median ORRs were 68.9%and 55.7%,respectively.The treatment effect in this Chinese subpopulation showed consistency with that in the global ITT population with numerically lower HR for OS and PFS compared with the control group.The safety profiles of the pertuzumab and control groups in this Chinese subpopulation analysis were generally comparable.The most common grade 3-5adverse events were neutropenia,anemia,and leukopenia.However,due to the nature of being a post hoc subgroup analysis,the results presented here are descriptive only and need to be interpreted with caution.Conclusions:OS and PFS were numerically improved by adding pertuzumab to trastuzumab and chemotherapy as first-line treatment in Chinese HER2-positive gastric cancer/GEJC patients,and this regimen demonstrated an acceptable safety profile. 关 键 词：Gastric cancer Gastroesophageal junction cancer HER2 PERTUZUMAB TRASTUZUMAB CHEMOTHERAPY Overall survival Progression-free survival Safety China
相关文献

参考文献(28)

引证文献(8)

耦合文献(25)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费